Inhibitors targeting Bruton’s tyrosine kinase (BTK), Phosphoinositide 3-kinases (PI3K) and B cell Lymphoma 2 (BCL2) have revolutionized treatment of CLL, but many patients are refractory or develop resistance, and CLL remains an incurable disease. Here, BTK is linked to B-cell chronic lymphocytic leukemia.